These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Immunogenicity and tolerance of ascending doses of a recombinant protective antigen (rPA102) anthrax vaccine: a randomized, double-blinded, controlled, multicenter trial. Gorse GJ; Keitel W; Keyserling H; Taylor DN; Lock M; Alves K; Kenner J; Deans L; Gurwith M Vaccine; 2006 Aug; 24(33-34):5950-9. PubMed ID: 16797805 [TBL] [Abstract][Full Text] [Related]
4. Effect of reduced dose schedules and intramuscular injection of anthrax vaccine adsorbed on immunological response and safety profile: a randomized trial. Wright JG; Plikaytis BD; Rose CE; Parker SD; Babcock J; Keitel W; El Sahly H; Poland GA; Jacobson RM; Keyserling HL; Semenova VA; Li H; Schiffer J; Dababneh H; Martin SK; Martin SW; Marano N; Messonnier NE; Quinn CP Vaccine; 2014 Feb; 32(8):1019-28. PubMed ID: 24373307 [TBL] [Abstract][Full Text] [Related]
5. Phase II safety and immunogenicity study of type F botulinum toxoid in adult volunteers. Edelman R; Wasserman SS; Bodison SA; Perry JG; O'Donnoghue M; DeTolla LJ Vaccine; 2003 Oct; 21(27-30):4335-47. PubMed ID: 14505916 [TBL] [Abstract][Full Text] [Related]
6. Evaluation of neutralizing antibodies to type A, B, E, and F botulinum toxins in sera from human recipients of botulinum pentavalent (ABCDE) toxoid. Siegel LS J Clin Microbiol; 1989 Aug; 27(8):1906-8. PubMed ID: 2768475 [TBL] [Abstract][Full Text] [Related]
7. Anthrax vaccine: immunogenicity and safety of a dose-reduction, route-change comparison study in humans. Pittman PR; Kim-Ahn G; Pifat DY; Coonan K; Gibbs P; Little S; Pace-Templeton JG; Myers R; Parker GW; Friedlander AM Vaccine; 2002 Jan; 20(9-10):1412-20. PubMed ID: 11818160 [TBL] [Abstract][Full Text] [Related]
9. Human immune response to botulinum pentavalent (ABCDE) toxoid determined by a neutralization test and by an enzyme-linked immunosorbent assay. Siegel LS J Clin Microbiol; 1988 Nov; 26(11):2351-6. PubMed ID: 3235662 [TBL] [Abstract][Full Text] [Related]
11. Effect of priming with diphtheria and tetanus toxoids combined with whole-cell pertussis vaccine or with acellular pertussis vaccine on the safety and immunogenicity of a booster dose of an acellular pertussis vaccine containing a genetically inactivated pertussis toxin in fifteen- to twenty-one-month-old children. Italian Multicenter Group for the Study of Recombinant Acellular Pertussis Vaccine. Podda A; Bona G; Canciani G; Pistilli AM; Contu B; Furlan R; Meloni T; Stramare D; Titone L; Rappuoli R J Pediatr; 1995 Aug; 127(2):238-43. PubMed ID: 7636648 [TBL] [Abstract][Full Text] [Related]
12. Validation and long term performance characteristics of a quantitative enzyme linked immunosorbent assay (ELISA) for human anti-PA IgG. Semenova VA; Schiffer J; Steward-Clark E; Soroka S; Schmidt DS; Brawner MM; Lyde F; Thompson R; Brown N; Foster L; Fox S; Patel N; Freeman AE; Quinn CP J Immunol Methods; 2012 Feb; 376(1-2):97-107. PubMed ID: 22197974 [TBL] [Abstract][Full Text] [Related]
13. Safety and immunogenicity of increasing doses of a Clostridium difficile toxoid vaccine administered to healthy adults. Kotloff KL; Wasserman SS; Losonsky GA; Thomas W; Nichols R; Edelman R; Bridwell M; Monath TP Infect Immun; 2001 Feb; 69(2):988-95. PubMed ID: 11159994 [TBL] [Abstract][Full Text] [Related]
14. Anthrax vaccine adsorbed: further evidence supporting continuing the vaccination series rather than restarting the series when doses are delayed. Pittman PR; Cavicchia MA; Kingsbury JL; Johnson NA; Barrera-Oro JG; Schmader T; Korman L; Quinn X; Ranadive M Vaccine; 2014 Sep; 32(39):5131-9. PubMed ID: 24837771 [TBL] [Abstract][Full Text] [Related]
15. Bridging non-human primate correlates of protection to reassess the Anthrax Vaccine Adsorbed booster schedule in humans. Schiffer JM; Chen L; Dalton S; Niemuth NA; Sabourin CL; Quinn CP Vaccine; 2015 Jul; 33(31):3709-16. PubMed ID: 26072016 [TBL] [Abstract][Full Text] [Related]
16. Production and immunogenic efficacy of botulinum tetravalent (A, B, E, F) toxoid. Torii Y; Tokumaru Y; Kawaguchi S; Izumi N; Maruyama S; Mukamoto M; Kozaki S; Takahashi M Vaccine; 2002 Jun; 20(19-20):2556-61. PubMed ID: 12057613 [TBL] [Abstract][Full Text] [Related]
17. Safety, reactogenicity and immunogenicity of a recombinant protective antigen anthrax vaccine given to healthy adults. Campbell JD; Clement KH; Wasserman SS; Donegan S; Chrisley L; Kotloff KL Hum Vaccin; 2007; 3(5):205-11. PubMed ID: 17881903 [TBL] [Abstract][Full Text] [Related]
18. Development of a competitive enzyme linked immunosorbent assay to identify epitope specific antibodies in recipients of the U.S. licensed anthrax vaccine. Gubbins MJ; Schmidt L; Tsang RS; Berry JD; Kabani A; Stewart DI J Immunoassay Immunochem; 2007; 28(3):213-25. PubMed ID: 17613668 [TBL] [Abstract][Full Text] [Related]
19. The immunogenicity in humans of a botulinum type F vaccine. Montgomery VA; Makuch RS; Brown JE; Hack DC Vaccine; 1999 Nov; 18(7-8):728-35. PubMed ID: 10547433 [TBL] [Abstract][Full Text] [Related]
20. The impact of incomplete vaccination schedules on the magnitude and duration of protective antigen-specific IgG responses in recipients of the US licensed anthrax vaccine. Lininger LA; Cullum ME; Lyles MB; Bienek DR Vaccine; 2007 Feb; 25(9):1619-25. PubMed ID: 17150286 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]